Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo test aims to spot hidden heart risk after attack

NCT ID NCT07268391

Knowledge-focused Sponsor: Instituto de Investigación Biomédica de Salamanca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times

Summary

This study looks at whether combining a new type of CT scan with a blood test for tiny molecules called microRNAs can better predict heart damage after a heart attack. Researchers will follow 95 patients who had a severe heart attack and measure changes in their heart size over six months. The goal is to create a model that identifies high-risk patients early, so they can get closer monitoring and tailored care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a new way to predict which heart attack patients are at risk of heart failure, allowing doctors to monitor them more closely and adjust treatments early.
What could go wrong
This is an early observational study with only 95 participants, so results may not apply to everyone. The new imaging and blood tests may not prove more useful than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 95 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥18 years. * First STEMI treated with primary PCI. * Left ventricular ejection fraction (LVEF) ≤45% during index hospitalization. * Ability to provide informed consent. Exclusion Criteria: * Contraindication to iodinated contrast media. * Chronic kidney disease with eGFR \<30 mL/min/1.73 m². * Prior myocardial infarction or known cardiomyopathy. * Contraindication to CT or MRI imaging. * Life expectancy \<1 year due to non-cardiac conditions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction (AMI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Complejo Asistencial Universitario de Salamanca

    RECRUITING

    Salamanca, Spain

  • Hospital Clínico Universitario de Valencia

    RECRUITING

    Valencia, Spain

  • Hospital La Princesa

    RECRUITING

    Madrid, Spain

  • Hospital Ramón y Cajal

    RECRUITING

    Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.